An unhealthy combination of factors resulted in an unhealthy day on the stock market for next-generation healthcare company BioNTech (NASDAQ: BNTX). Investors were concerned about the latest top-level ...

BioNTech has a rich pipeline that could help jolt the stock as it makes clinical progress. Intellia Therapeutics faces ...

The type of vaccine it's most famous for might be cast in a very unflattering light in the very near future.. Citing four unnamed people "familiar with the situation," this effort will be based on ...

In the latest quarter, 6 analysts provided ratings for BioNTech (NASDAQ:BNTX), showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below illustrates ...

We came across a bullish thesis on BioNTech SE on Memyselfandi007’s Substack. In this article, we will summarize the bulls’ thesis on BNTX. BioNTech SE’s share was trading at $103.80 as of March 4th.

BioNTech’s fair value estimate has been trimmed from $139.51 to $131.39, a modest cut of about 6% that reflects the latest model inputs. This shift comes as analysts reassess the story around ...

BioNTech, a biotech company best known for its successful development of a messenger RNA Covid-19 vaccine, is acquiring fellow mRNA company CureVac in a $1.25 billion stock deal that brings together ...

BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. The recent acquisition of CureVac and the deal with Bristol Myers Squibb validate ...

German biopharma outfit BioNTech SE reported lackluster fiscal Q4 results on Tuesday. Guidance for the year now underway is just as disappointing. The creators of this company’s breakthrough science ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...